SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series

被引：13
|
作者：
Zampieri, Mattia [1 ,2 ]
Argiro, Alessia [1 ,2 ]
Allinovi, Marco [1 ]
Perfetto, Federico [1 ,3 ]
Cappelli, Francesco [1 ,4 ]
机构：
[1] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Largo Brambilla 3, I-50134 Florence, Italy
[2] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy
[3] Careggi Univ Hosp, IV Internal Med Div, Florence, Italy
[4] Careggi Univ Hosp, Div Intervent Struct Cardiol, Cardiothoracovasc Dept, Florence, Italy
来源：
INTERNAL AND EMERGENCY MEDICINE | 2022年 / 17卷 / 04期
关键词：
Amyloidosis; SGLT2i; Heart failure; Diabetes; Empaglifozin; Dapagliflozin; Canagliflozin;
D O I：
10.1007/s11739-022-02944-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1243 / 1245
页数：3
相关论文
共 50 条
  • [41] Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry
    Stolfo, Davide
    Lund, Lars H.
    Benson, Lina
    Lindberg, Felix
    Ferrannini, Giulia
    Dahlstrom, Ulf
    Sinagra, Gianfranco
    Rosano, Giuseppe M. C.
    Savarese, Gianluigi
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (09) : 1648 - 1658
  • [42] Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)-A Real World Retrospective Study from India
    Padhye, Dakshata
    Seshadri, Krishna
    DIABETES, 2024, 73
  • [43] Real-world Characteristics of Patients With Heart Failure in China: Baseline Results From The Retrospective Non-interventional Nationwide Study (REPRESENT-HF)
    Zhou, Jingmin
    Li, Xinli
    Dong, Yugang
    Yang, Jiefu
    Huo, Yong
    Ge, Junbo
    CIRCULATION, 2019, 140
  • [44] Prevalence of cardiac abnormalities and heart failure in unselected out-patients with type 2 diabetes mellitus and associated clinical factors: Real-world evidence from an Indian registry
    Rajput, Rajesh
    Mohan, J. C.
    Sawhney, J. P. S.
    Dalal, Jamshed
    Mullasari, Ajit
    Vasnawala, Hardik
    Kumar, Amit
    Hs, Bharath
    Sarda, Shital
    INDIAN HEART JOURNAL, 2023, 75 (06) : 436 - 442
  • [45] The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings
    Mazza, Alberto
    Townsend, Danyelle M.
    Torin, Gioia
    Schiavon, Laura
    Camerotto, Alessandro
    Rigatelli, Gianluca
    Cuppini, Stefano
    Minuz, Pietro
    Rubello, Domenico
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 130
  • [46] Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
    Kosiborod, Mikhail
    Birkeland, Kare I.
    Cavender, Matthew A.
    Fu, Alex Z.
    Wilding, John P.
    Khunti, Kamlesh
    Holl, Reinhard W.
    Norhammar, Anna
    Jorgensen, Marit E.
    Wittbrodt, Eric T.
    Thuresson, Marcus
    Bodegard, Johan
    Hammar, Niklas
    Fenici, Peter
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1983 - 1987
  • [47] Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
    Stolfo, D. Davide
    Lund, L.
    Benson, L.
    Lindberg, F.
    Dahlstrom, U.
    Sinagra, G.
    Rosano, G.
    Savarese, G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 192 - 192
  • [48] Real-world treatment patterns in patients with HER2+unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort
    Lee, Soo-Chin
    Chung, Wei-Pang
    Ngan, Roger Kai-Cheong
    Im, Seock-Ah
    Hui, Rina
    Barrios, Carlos
    Tung, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] The gap between real-world and guidelines in the use of sodium-glucose cotransporter 2 inhibitors for heart failure patients with reduced ejection fraction: Is it underestimated or overestimated? Letter regarding the article 'Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry'
    Zhao, Yuqin
    Sun, Jun
    Xie, Cheng
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (03) : 704 - 705
  • [50] SACUBITRIL/VALSARTAN REAL-WORLD PERSISTENCE USING A COHORT OF HEART FAILURE PATIENTS FROM THE PRESCRIPTION & MONITORING OF SACUBITRIL/VALSARTAN STUDY (PRIME 2 STUDY)
    Teixeira Rodrigues, A.
    Murteira, R.
    Bulhosa, C.
    Cary, M.
    Guerreiro, J.
    Laires, P. A.
    Afonso-Silva, M.
    VALUE IN HEALTH, 2020, 23 : S505 - S505
12345